AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20370452 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall mupirocin application
Number of subjects: 33
Study 18349395 — intervention group
Group type: EXPERIMENTAL
Intervention: EGF vaccinations
Number of subjects: 80
Study 18349395 — intervention group
Group type: COMPARATOR
Intervention: Best supportive care
Number of subjects: 80
Study 17163233 — intervention group
Group type: COMPARATOR
Intervention: 7.5 mg of 0.5% hyperbaric bupivacaine (Group B)
Number of subjects: 40
Study 17163233 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg of 0.66% hyperbaric ropivacaine (Group R)
Number of subjects: 40
Study 15071253 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial therapies ON
Number of subjects: 0
Study 15071253 — intervention group
Group type: COMPARATOR
Intervention: Atrial therapies OFF
Number of subjects: 0
Study 10749277 — intervention group
Group type: EXPERIMENTAL
Intervention: Critical Time Intervention (CTI)
Number of subjects: 96
Study 10749277 — intervention group
Group type: COMPARATOR
Intervention: Usual services only
Number of subjects: 96
Study 8933485 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive resistance strength training at 80% of one-repetition maximum, 8 repetitions per set, 3 sets per session, twice weekly for 12 weeks.
Number of subjects: 24
Study 8933485 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy elderly nontraining subjects).
Number of subjects: 24
Study 7921445 — intervention group
Group type: EXPERIMENTAL
Intervention: KS1/4-methotrexate (KS1/4-MTX) immunoconjugate, maximal tolerated dose of 1,750 mg/M2, cumulative dose of MTX of 40 mg/M2
Number of subjects: 11
Study 7921445 — intervention group
Group type: EXPERIMENTAL
Intervention: KS1/4-methotrexate (KS1/4-MTX) immunoconjugate
Number of subjects: 11
Study 3135144 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg oral lithium carbonate load (8.1 mmol of elemental lithium)
Number of subjects: 0
Study 31841156 — intervention group
Group type: EXPERIMENTAL
Intervention: SupportBack Internet intervention with physiotherapist telephone guidance
Number of subjects: 15
Study 31841156 — intervention group
Group type: COMPARATOR
Intervention: SupportBack Internet intervention without physiotherapist telephone guidance
Number of subjects: 15
Study 29746388 — intervention group
Group type: EXPERIMENTAL
Intervention: β-Alanine (BA)
Number of subjects: 20
Study 29746388 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 20
Study 28126631 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild Cognitive Impairment (MCI) group
Number of subjects: 37
Study 28126631 — intervention group
Group type: EXPERIMENTAL
Intervention: All-capital-letters task
Number of subjects: 37
Study 26207129 — intervention group
Group type: EXPERIMENTAL
Intervention: Clzapine (generic formulation) 100 mg twice daily for 10 days
Number of subjects: 28
Study 26207129 — intervention group
Group type: COMPARATOR
Intervention: Clozaril (brand name formulation) 100 mg twice daily for 10 days
Number of subjects: 28
Study 24114865 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose β-blocker (≥50 mg daily equivalent dose of metoprolol succinate)
Number of subjects: 151
Study 24114865 — intervention group
Group type: COMPARATOR
Intervention: Low-dose β-blocker (<50 mg daily equivalent dose of metoprolol succinate)
Number of subjects: 151
Study 24114865 — intervention group
Group type: COMPARATOR
Intervention: Low-dose β-blocker with high sST2
Number of subjects: 151
Study 24114865 — intervention group
Group type: COMPARATOR
Intervention: Low-dose β-blocker with low sST2
Number of subjects: 151
Study 24114865 — intervention group
Group type: COMPARATOR
Intervention: High-dose β-blocker with high sST2
Number of subjects: 151
Study 20820172 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise intervention (45 minutes of moderate-to-vigorous aerobic exercise five times per week for 1 year)
Number of subjects: 320
Study 18650733 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic alendronate for 4 months starting the day of surgery (group 3)
Number of subjects: 40
Study 18650733 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic alendronate + postextractive endoalveolar collagen sponge (group 4)
Number of subjects: 40
Study 18650733 — intervention group
Group type: COMPARATOR
Intervention: Postextractive endoalveolar collagen sponge (group 2)
Number of subjects: 40
Study 18650733 — intervention group
Group type: COMPARATOR
Intervention: No medication (group 1)
Number of subjects: 40
Study 17049927 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive‐behavioral intervention (CBI)
Number of subjects: 104
Study 17049927 — intervention group
Group type: COMPARATOR
Intervention: Treatment with counseling as usual (TAU)
Number of subjects: 104
Study 12624515 — intervention group
Group type: EXPERIMENTAL
Intervention: Flow cytometry with propidium iodide staining and anti-cytokeratin antibodies
Number of subjects: 30
Study 12624515 — intervention group
Group type: EXPERIMENTAL
Intervention: Double labelling technique with cytokeratin-staining
Number of subjects: 30
Study 12624515 — intervention group
Group type: COMPARATOR
Intervention: Forceps biopsies
Number of subjects: 30
Study 10693733 — intervention group
Group type: EXPERIMENTAL
Intervention: SunSafe intervention
Number of subjects: 261
Study 10693733 — intervention group
Group type: COMPARATOR
Intervention: Control town parents
Number of subjects: 261
Study 7568736 — intervention group
Group type: EXPERIMENTAL
Intervention: Counterrotational electric toothbrush
Number of subjects: 20
Study 7568736 — intervention group
Group type: COMPARATOR
Intervention: Manual toothbrush
Number of subjects: 20
Study 2405623 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose calcium heparin
Number of subjects: 0
Study 2405623 — intervention group
Group type: COMPARATOR
Intervention: Low-dose calcium heparin
Number of subjects: 0
Study 7380584 — intervention group
Group type: EXPERIMENTAL
Intervention: Mianserin
Number of subjects: 18
Study 7380584 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 18
Study 7380584 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 30787664 — intervention group
Group type: EXPERIMENTAL
Intervention: Foam rolling (short duration 20s)
Number of subjects: 53
Study 30787664 — intervention group
Group type: EXPERIMENTAL
Intervention: Foam rolling (long duration 40s)
Number of subjects: 53
Study 30787664 — intervention group
Group type: EXPERIMENTAL
Intervention: Joint distraction with elastic band training
Number of subjects: 53
Study 30787664 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 53
Study 27106713 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindset intervention
Number of subjects: 726
Study 27106713 — intervention group
Group type: COMPARATOR
Intervention: Content writing task
Number of subjects: 726
Study 25651595 — intervention group
Group type: EXPERIMENTAL
Intervention: Creative dance program for 24 weeks
Number of subjects: 57
Study 25651595 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 57
Study 22840783 — intervention group
Group type: EXPERIMENTAL
Intervention: GAD1 gene risk variants (tSNP rs3828275)
Number of subjects: 257
Study 22840783 — intervention group
Group type: EXPERIMENTAL
Intervention: GAD1 gene risk variants (tSNP rs769391 and functional SNP rs3791878)
Number of subjects: 257
Study 22840783 — intervention group
Group type: COMPARATOR
Intervention: Subjects with 0-1 risk variant
Number of subjects: 257
Study 22840783 — intervention group
Group type: EXPERIMENTAL
Intervention: Haplotypes with both risk variants
Number of subjects: 257
Study 22840783 — intervention group
Group type: EXPERIMENTAL
Intervention: Diplotype with 2 copies of the haplotype containing both risk alleles
Number of subjects: 257
Study 20825817 — intervention group
Group type: EXPERIMENTAL
Intervention: Point-of-care chemistry test (POCT)
Number of subjects: 2323
Study 20825817 — intervention group
Group type: COMPARATOR
Intervention: Traditional central laboratory test (CLT)
Number of subjects: 2323
Study 19034910 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-pathway model of overeating
Number of subjects: 153
Study 17908768 — intervention group
Group type: EXPERIMENTAL
Intervention: Overweight group (BMI for age: > or = 95th percentile)
Number of subjects: 1005
Study 17908768 — intervention group
Group type: EXPERIMENTAL
Intervention: Overweight risk group (BMI for age: 85th to < 95th percentile)
Number of subjects: 1005
Study 17908768 — intervention group
Group type: EXPERIMENTAL
Intervention: Overweight group
Number of subjects: 1005
Study 17908768 — intervention group
Group type: COMPARATOR
Intervention: General population of children in the United States
Number of subjects: 1005
Study 17908768 — intervention group
Group type: EXPERIMENTAL
Intervention: Black and Hispanic children
Number of subjects: 1005
Study 15331679 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower body negative pressure (LBNP) ‐20 mmHg in +RA subjects
Number of subjects: 23
Study 15331679 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower body negative pressure (LBNP) ‐20 mmHg in ‐RA subjects
Number of subjects: 23
Study 15331679 — intervention group
Group type: COMPARATOR
Intervention: Lower body negative pressure (LBNP) ‐40 mmHg in controls
Number of subjects: 23
Study 15331679 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower body negative pressure (LBNP) ‐40 mmHg in +RA subjects
Number of subjects: 23
Study 15331679 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower body negative pressure (LBNP) ‐40 mmHg in ‐RA subjects
Number of subjects: 23
Study 15331679 — intervention group
Group type: EXPERIMENTAL
Intervention: Systolic blood pressure (SBP) response to LBNP ‐40 mmHg in ‐RA subjects
Number of subjects: 23
Study 15331679 — intervention group
Group type: EXPERIMENTAL
Intervention: Systolic blood pressure (SBP) response to LBNP ‐40 mmHg in +RA subjects
Number of subjects: 23
Study 15331679 — intervention group
Group type: COMPARATOR
Intervention: Systolic blood pressure (SBP) response to LBNP ‐40 mmHg in controls
Number of subjects: 23
Study 15331679 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart rate response from baseline to LBNP ‐40 mmHg in ‐RA subjects
Number of subjects: 23
Study 11247108 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine (5 to 20 mg/day)
Number of subjects: 676
Study 11247108 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol (5 to 20 mg/day)
Number of subjects: 676
Study 11247108 — intervention group
Group type: COMPARATOR
Intervention: Olanzapine vs Haloperidol
Number of subjects: 676
Study 9754892 — intervention group
Group type: EXPERIMENTAL
Intervention: ATHU-test (AHEPA Thromb Haem Unit)
Number of subjects: 20
Study 9754892 — intervention group
Group type: EXPERIMENTAL
Intervention: ATHU-test
Number of subjects: 20
Study 9754892 — intervention group
Group type: EXPERIMENTAL
Intervention: In vitro addition of LMWH (1.5 u aXa/ml)
Number of subjects: 20
Study 7722707 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional supplementation (100 kcal/d) during the first year of life
Number of subjects: 1208
Study 7722707 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional supplementation (100 kcal/d) during the second year of life
Number of subjects: 1208
Study 7722707 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional supplementation between 24 and 36 months of age
Number of subjects: 1208
Study 7722707 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional supplementation between 3 and 7 years of age
Number of subjects: 1208
Study 2816762 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous diltiazem
Number of subjects: 42
Study 2816762 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 1111271 — intervention group
Group type: EXPERIMENTAL
Intervention: Informational load of 1, 2, and 3 bits; manual motion distances of 7 inches and 14 inches.
Number of subjects: 5
Study 30113394 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam premedication
Number of subjects: 97
Study 30113394 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 97
Study 28825663 — intervention group
Group type: EXPERIMENTAL
Intervention: Letibotulinumtoxin A
Number of subjects: 144
Study 28825663 — intervention group
Group type: EXPERIMENTAL
Intervention: Onabotulinumtoxin A
Number of subjects: 144
Study 26157206 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurac training (30 min/day, 3 days/week for 4 weeks)
Number of subjects: 20
Study 26157206 — intervention group
Group type: COMPARATOR
Intervention: Traditional physical therapy (30 min/session, 3 sessions/week for 4 weeks)
Number of subjects: 20
Study 23475153 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT)
Number of subjects: 0
Study 23475153 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual (TAU)
Number of subjects: 0
Study 21707176 — intervention group
Group type: EXPERIMENTAL
Intervention: Working memory training
Number of subjects: 0
Study 21707176 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 19381808 — intervention group
Group type: EXPERIMENTAL
Intervention: Neighborhood strength
Number of subjects: 5655
Study 19381808 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to alcohol advertisements
Number of subjects: 5655
Study 19381808 — intervention group
Group type: EXPERIMENTAL
Intervention: Commercial alcohol access
Number of subjects: 5655
Study 19381808 — intervention group
Group type: EXPERIMENTAL
Intervention: Home alcohol access
Number of subjects: 5655
Study 16943451 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil plus 100 mg vitamin E
Number of subjects: 40
Study 16943451 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil plus 200 mg vitamin E
Number of subjects: 40
Study 16943451 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil plus 400 mg vitamin E
Number of subjects: 40
Study 16943451 — intervention group
Group type: COMPARATOR
Intervention: Fish oil only (control)
Number of subjects: 40
Study 15364138 — intervention group
Group type: COMPARATOR
Intervention: Whole brain radiotherapy (WBRT) alone (20Gy in five fractions)
Number of subjects: 42
Study 15364138 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole brain radiotherapy plus concomitant carboplatin (70 mg/m(2) intravenously for 5 days)
Number of subjects: 42
Study 15364138 — intervention group
Group type: COMPARATOR
Intervention: Whole brain radiotherapy (RT) arm
Number of subjects: 42
Study 15364138 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole brain radiotherapy plus concomitant carboplatin (RTC) arm
Number of subjects: 42
Study 10660240 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% ropivacaine (0.125 mg/kg/h)
Number of subjects: 60
Study 10660240 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% ropivacaine (0.25 mg/kg/h)
Number of subjects: 60
Study 10660240 — intervention group
Group type: COMPARATOR
Intervention: Saline (6 to 11 mL/h)
Number of subjects: 60
Study 10660240 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (0.1% ropivacaine, 0.2% ropivacaine, saline)
Number of subjects: 60
Study 10660240 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 60
Study 9549636 — intervention group
Group type: EXPERIMENTAL
Intervention: Riluzole 50 mg tablet
Number of subjects: 0
Study 9549636 — intervention group
Group type: EXPERIMENTAL
Intervention: Riluzole 100 mg for 10 days
Number of subjects: 0
Study 9549636 — intervention group
Group type: COMPARATOR
Intervention: Riluzole with high-fat meal
Number of subjects: 0
Study 9549636 — intervention group
Group type: EXPERIMENTAL
Intervention: Riluzole 75 mg twice daily
Number of subjects: 0
Study 9549636 — intervention group
Group type: COMPARATOR
Intervention: Riluzole 50 mg three times daily
Number of subjects: 0
Study 9549636 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple-dose administration of riluzole
Number of subjects: 0
Study 8157048 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg i.v. dose of flumazenil
Number of subjects: 18
Study 8157048 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg oral dose of flumazenil
Number of subjects: 18
Study 3895918 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftazidime (50 mg/kg intravenously every eight hours)
Number of subjects: 100
Study 3895918 — intervention group
Group type: COMPARATOR
Intervention: Ampicillin plus chloramphenicol (conventional dosages)
Number of subjects: 100
Study 3895918 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftazidime
Number of subjects: 100
Study 3895918 — intervention group
Group type: COMPARATOR
Intervention: Ampicillin plus chloramphenicol
Number of subjects: 100
Study 30196968 — intervention group
Group type: EXPERIMENTAL
Intervention: HFF/CGC‐IVM
Number of subjects: 47
Study 30196968 — intervention group
Group type: COMPARATOR
Intervention: S‐IVM
Number of subjects: 47
Study 30196968 — intervention group
Group type: COMPARATOR
Intervention: AFF‐IVM
Number of subjects: 47
Study 30196968 — intervention group
Group type: COMPARATOR
Intervention: HFF‐IVM
Number of subjects: 47
Study 26990651 — intervention group
Group type: EXPERIMENTAL
Intervention: Amplitude training (experimental group, n = 18)
Number of subjects: 38
Study 26990651 — intervention group
Group type: COMPARATOR
Intervention: Stretch and relaxation exercises (placebo group, n = 20)
Number of subjects: 38
Study 24472587 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate-rich fluid group
Number of subjects: 44
Study 24472587 — intervention group
Group type: COMPARATOR
Intervention: Usual care group
Number of subjects: 44
Study 22891356 — intervention group
Group type: EXPERIMENTAL
Intervention: DCE MR imaging
Number of subjects: 29
Study 22891356 — intervention group
Group type: EXPERIMENTAL
Intervention: DCE CT
Number of subjects: 29
Study 22891356 — intervention group
Group type: EXPERIMENTAL
Intervention: DCE MR imaging and DCE CT
Number of subjects: 29
Study 19305278 — intervention group
Group type: EXPERIMENTAL
Intervention: Mears technique
Number of subjects: 21
Study 17207678 — intervention group
Group type: EXPERIMENTAL
Intervention: Circuit Resistance Training (CRT)
Number of subjects: 7
Study 15254055 — intervention group
Group type: COMPARATOR
Intervention: Regimen A (vincristine 2 mg/m(2), cyclophosphamide 1,200 mg/m(2), doxorubicin 75 mg/m(2) or dactinomycin 1.25 mg/m(2))
Number of subjects: 120
Study 15254055 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen B (Regimen A alternating every 3 weeks with ifosfamide 1,800 mg/m(2)/d for 5 days and etoposide 100 mg/m(2)/d for 5 days)
Number of subjects: 120
Study 15254055 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with only lung metastases
Number of subjects: 120
Study 15254055 — intervention group
Group type: EXPERIMENTAL
Intervention: Toxic deaths
Number of subjects: 120
Study 11480629 — intervention group
Group type: EXPERIMENTAL
Intervention: A/V eyeglass system
Number of subjects: 27
Study 11480629 — intervention group
Group type: COMPARATOR
Intervention: Traditional treatment (no A/V eyeglasses)
Number of subjects: 27
Study 9493260 — intervention group
Group type: EXPERIMENTAL
Intervention: New randomization-based procedure with Bayesian analysis under the exclusion hypothesis
Number of subjects: 0
Study 9493260 — intervention group
Group type: COMPARATOR
Intervention: Standard intent-to-treat procedure
Number of subjects: 0
Study 7946694 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic carpal tunnel decompression
Number of subjects: 18
Study 7946694 — intervention group
Group type: COMPARATOR
Intervention: Traditional surgical treatment of open carpal tunnel decompression
Number of subjects: 18
Study 3060211 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (low-dose)
Number of subjects: 15
Study 3060211 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 3060211 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (long-term)
Number of subjects: 15
Study 7438771 — intervention group
Group type: EXPERIMENTAL
Intervention: Mefenamic acid
Number of subjects: 87
Study 7438771 — intervention group
Group type: COMPARATOR
Intervention: Dextropropoxyphene plus paracetamol
Number of subjects: 87
Study 31733490 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic cranial irradiation (PCI)
Number of subjects: 174
Study 31733490 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 174
Study 31101694 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% isobaric bupivacaine (1.15-1.70 mL) injected into the subarachnoid space without prophylactic vasopressors
Number of subjects: 264
Study 31101694 — intervention group
Group type: COMPARATOR
Intervention: 0.5% bupivacaine (1.8 mL) injected into the subarachnoid space along with prophylactic vasopressors
Number of subjects: 264
Study 31101694 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% isobaric bupivacaine (1.15-1.70 mL)
Number of subjects: 264
Study 31101694 — intervention group
Group type: COMPARATOR
Intervention: 0.5% bupivacaine (1.8 mL) with prophylactic vasopressors
Number of subjects: 264
Study 27491027 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacral neuromodulation (SNM) therapy with the InterStim® System
Number of subjects: 272
Study 25915772 — intervention group
Group type: EXPERIMENTAL
Intervention: Central PRO coordinator
Number of subjects: 231
Study 25915772 — intervention group
Group type: COMPARATOR
Intervention: No PRO coordinator
Number of subjects: 231
Study 23921584 — intervention group
Group type: EXPERIMENTAL
Intervention: RHANI Wives HIV intervention
Number of subjects: 220
Study 23921584 — intervention group
Group type: COMPARATOR
Intervention: Basic HIV prevention education (Control)
Number of subjects: 220
Study 21248183 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation
Number of subjects: 127
Study 21248183 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 127
Study 18978177 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistant starch (RS)
Number of subjects: 65
Study 18978177 — intervention group
Group type: COMPARATOR
Intervention: Ordinary starch (OS)
Number of subjects: 65
Study 17304501 — intervention group
Group type: EXPERIMENTAL
Intervention: Tritherapy strategy 1
Number of subjects: 0
Study 17304501 — intervention group
Group type: COMPARATOR
Intervention: Tritherapy strategy 2
Number of subjects: 0
Study 15491578 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone 100 mg
Number of subjects: 1000
Study 15491578 — intervention group
Group type: COMPARATOR
Intervention: Yuzpe regimen
Number of subjects: 1000
Study 11427836 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance endoscopic variceal ligation (EVL)
Number of subjects: 109
Study 11427836 — intervention group
Group type: COMPARATOR
Intervention: Demand endoscopic variceal ligation (EVL)
Number of subjects: 109